Code Biotherapeutics Raises $75M in Series A
Jun 9, 2022
Back to HomeHATFIELD, PA, Code Biotherapeutics, a biotechnology company, announced its Series A financing of $75 million led by Northpond Ventures.Code Biotherapeutics, a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announced its upsized and oversubscribed Series A financing of $75 million to advance programs to treat and cure rare and prevalent genetic diseases.Northpond Ventures led the financing round with participation from Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, the JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.